MUTATION 'REFRACTION'BROAD SPECTRUM ANTI-HEPATITIS DRUG

Callisto Pharmaceuticals, Inc., New York NY

Investigators

Linked publications & trials

Abstract

DESCRIPTION (Adapted from Applicant's Abstract): The investigator plans to determine the feasibility of using glucosidase inhibitors as anti-hepatitis B and C virus agents. These phase I studies will determine if alpha-glucosidase inhibitors are effective in preventing the release and spread of lamivudine (3TC)-resistant mutants of HBV in cell culture. Studies to examine the frequency of spontaneously occurring glucosidase inhibitor mutants of bovine viral diarrhea virus, which will be used as a tissue culture model for HCV will also be performed. If such mutants arise, they will then be isolated and characterized. Future phase II studies will focus on modifying the imino sugar to enhance potency and will perform animal toxicity studies with the lead compound. Experiments to examine the efficacy of glucosidase inhibitors against 3TC-resistant mutants of woodchuck hepatitis virus in animals will also be expanded in the phase II studies. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE